NINTEDANIB HAD CONSISTENT EFFECT ON SLOWING THE RATE OF DECLINE OF FORCED VITAL CAPACITY IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS AND OTHER PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES, AND WITH SYSTEMIC SCLEROSIS-ASSOCIATED LUNG DISEASE

Abstract

Nintedanib is an antifibrotic drug, an intracellular tyrosine kinase receptor inhibitor. Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis, other progressive fibrosing interstitial lung diseases, and interstitial lung disease associated with systemic sclerosis. Nindetanib effectively slowed the decline in vital lung capacity in the treatment of these lung diseases, and this effect was long-lasting.